Neuron-specific enolase as a tumor marker in metastatic melanoma.
Neuron-specific enolase (NSE) has been shown by some investigators to be a useful tumor marker for melanoma, but the relationship between NSE and tumor burden has not been extensively studied. We therefore examined NSE levels in 240 patients of whom 169 had no clinical evidence of disease (NED) and 71 had metastatic disease. There was no statistically significant difference in NSE levels in patients with NED compared with metastatic disease as well as those with high tumor burden compared with low or intermediate tumor burden. In addition, the mean absolute values of NSE, despite a slight elevation with tumor burden, were within the normal range (< 20 ng/ml). Our data suggest that NSE levels measured by the method used in our study are of no benefit in melanoma.
Buzaid
A C
AC
University of Texas M. D. Anderson Cancer Center, Department of Melanoma/Sarcoma, Houston 77030.
Sandler
A B
AB
Hayden
C L
CL
Scinto
J
J
Poo
W J
WJ
Clark
M B
MB
Hotchkiss
S
S
D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008545:Melanoma / Q000201:enzymology* / Q000556:secondary; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D011446:Prospective Studies
D014408:Biomarkers, Tumor; D010751:Phosphopyruvate Hydratase